{"nctId":"NCT02327351","briefTitle":"TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID","startDateStruct":{"date":"2012-07","type":"ACTUAL"},"conditions":["Primary Immune Deficiency Disorder","Hematopoietic Stem Cell Transplantation"],"count":98,"armGroups":[{"label":"TCR alfa beta depletion","type":"EXPERIMENTAL","interventionNames":["Other: Biological: TCR alfa beta T cell depletion"]}],"interventions":[{"name":"Biological: TCR alfa beta T cell depletion","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged ≥ 1 months and \\< 19 years\n* Patients diagnosed with Primary Immunodeficiency Diseases eligible for an allogeneic transplantation and lacking a related HLA-matched donor\n* Lansky/Karnofsky score \\> 40, WHO \\> 4\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Dysfunction of liver (ALT/AST \\> 5 times normal value, or bilirubin \\> 3 times normal value), or of renal function (creatinine clearance \\< 30 ml / min)\n* Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction \\<40%)\n* Serious concurrent uncontrolled medical disorder\n* Pregnant or breast feeding female patient\n* Lack of parents' informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"The probability of overall survival estimated by the Kaplan-Meier method at 1 year after HSCT","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Transplant Related Mortality (TRM)","description":"transplant-related mortality estimated with cumulative incidence curve, considering relapse as a competitive risk","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Acute Graft Versus Host Diseases (аGVHD)","description":"incidence of aGVHD II-IV stage estimated with cumulative incidence curve, considering graft rejection and death as competitive risks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Chronic Graft Versus Host Diseases (cGVHD)","description":"incidence of cGVHD estimated with cumulative incidence curve, considering graft rejection and death as competitive risks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Cellular Immunological Reconstitution","description":"Number of participants, who reached immune recovery - CD19+ lymphocytes subsets","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Full Donor Chimerism","description":"Percentage of patients with full (more than 90%) donor chimerism among survivals","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Viral Infections After Transplant","description":"number of patients with CMV reactivation (detection of any grade of CMV viremia after HSCT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":98},"commonTop":[]}}}